MRVI
MARAVAI LIFESCIENCES HOLDINGS, INC.
NASDAQ · Healthcare · Biotechnology · US
$6.99
+2.95%Year over year
Reported trailing growth
- Revenue
- -3.3%
- EBITDA
- +77.9%
- EBIT
- +129.8%
- EPS
- +60.6%
- Free cash flow
- +21.5%
- Operating cash flow
- -19.4%
Forward estimates
Based on analyst estimates
- Revenue
- +4.5%
- EBITDA
- +195.1%
- EPS
- +77.4%
Three-year CAGR
- Revenue
- -40.5%
- EBITDA
- +6.0%
- EBIT
- +97.1%
- Net income
- +9.7%
- EPS
- +13.3%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026